Complement Factor B Blockade by Iptacopan Drives Antitumor Complement-Based Immunomodulation in Pancreatic Cancer Microenvironment (IMAGE)
Caption
A new study in The American Journal of Pathology demonstrates that blocking complement factor B (CFB) with iptacopan halts cancer growth and alters the tumor microenvironment, pointing to a promising new target in the treatment of pancreatic cancer. The greatest tumor suppression was observed when CFB inhibition was combined with chemotherapy and immunotherapy.A new study in The American Journal of Pathology demonstrates that blocking complement factor B (CFB) with iptacopan halts cancer growth and alters the tumor microenvironment, pointing to a promising new target in the treatment of pancreatic cancer. The greatest tumor suppression was observed when CFB inhibition was combined with chemotherapy and immunotherapy.
Credit
The American Journal of Pathology / Zhou et al.)
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND